This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data
Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data
Learn about funding and reimbursement for England, Scotland, Wales and Northern Ireland
Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
- Headaches (25%)1
- Arthralgia (16%)1
- Diarrhoea (13%)1
Abnormal liver results (≥1/100 to <1/10)1
- 3.2% of 2221 patients from ACROSTUDY had ALT/AST > 3 x ULN2
- Most elevations are transient with no reports of liver failure2
Injection site reactions (≥1/100 to <1/10)1
- 2% of 2221 patients from ACROSTUDY had treatment-related Injection site reactions2
- Most injection site reactions characterised as localised erythemas and soreness, spontaneously resolved with local symptomatic treatment, while pegvisomant therapy continued. Occurrence of injection site hypertrophy has been observed, including lipohypertrophy.1
Over 2000 patients have participated in ACROSTUDY, the global safety surveillance study for Somavert to date, providing a wealth of information about possible adverse events1,2
For full details on side effects and selected adverse reactions please refer to the Somavert Summary of Product Characteristics1
Liver function should be assessed at baseline and monitored every 4-6 weeks for the first 6 months of treatment, or at any time in patients exhibiting symptoms suggestive of hepatitis. More frequent if elevations are detected at baseline. For full details regarding the assessment and monitoring of liver function please refer to the Summary of Product Characteristics.1
Discover IGF-I normalisation rates with Somavert
To find out more about supporting your patients or to order starter kits
Help your patients feel confident with Somavert and self-administration
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021